Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | CD44 | P16070 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3992069 | 0.92 | POLB (0.34) | HTR2CPOLBSMN1; SMN2PNMTCD44 | |
| SCHEMBL1013890 | 0.73 | POLB (0.41) | HTR2CPOLBSMN1; SMN2PNMTCD44 | |
| SCHEMBL5761419 | 0.68 | — | — | |
| SCHEMBL21036380 | 0.68 | HTR2C (0.33) | HTR2CPNMTCD44 | |
| Hydrochloric Acid SCHEMBL21003163 | 0.67 | HTR2C (0.33) | HTR2CPNMTCD44 | |
| SCHEMBL2562162 | 0.67 | PNMT (0.43) | HTR2CPOLBSMN1; SMN2PNMTCD44 | |
| SCHEMBL2560588 | 0.67 | CHRNB2 (0.44) | HTR2CPNMTCD44MAOB | |
| SCHEMBL12333209 | 0.65 | HTR2A (0.35) | HTR2CPNMT | |
| SCHEMBL160968 | 0.65 | POLB (0.43) | HTR2CPOLBSMN1; SMN2PNMTCD44 | |
| SCHEMBL1868815 | 0.65 | HTR2C (0.33) | HTR2CPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | claimed |
| US-7544691-B2 | Guanidine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-06-09 | — | — | US | disclosed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123510-A1 | Guanidine derivatives | NPFFR1, NPFFR2, OGFR | HTR2C 583/4885POLB 1126/4885SMN1; SMN2 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.